HK1206344A1 - 作為 抑制劑的二氟-六氫-環戊二烯並噁嗪基類和二氟-六氫-苯並噁嗪基類 - Google Patents
作為 抑制劑的二氟-六氫-環戊二烯並噁嗪基類和二氟-六氫-苯並噁嗪基類Info
- Publication number
- HK1206344A1 HK1206344A1 HK15106931.2A HK15106931A HK1206344A1 HK 1206344 A1 HK1206344 A1 HK 1206344A1 HK 15106931 A HK15106931 A HK 15106931A HK 1206344 A1 HK1206344 A1 HK 1206344A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bace1
- ang
- vegf
- antibodies
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12173690 | 2012-06-26 | ||
| PCT/EP2013/063086 WO2014001228A1 (en) | 2012-06-26 | 2013-06-24 | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1206344A1 true HK1206344A1 (zh) | 2016-01-08 |
Family
ID=48672630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106931.2A HK1206344A1 (zh) | 2012-06-26 | 2015-07-21 | 作為 抑制劑的二氟-六氫-環戊二烯並噁嗪基類和二氟-六氫-苯並噁嗪基類 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9181232B2 (zh) |
| EP (1) | EP2864324B1 (zh) |
| JP (1) | JP6251257B2 (zh) |
| KR (1) | KR20150023450A (zh) |
| CN (1) | CN104470915B (zh) |
| AU (1) | AU2013283524B2 (zh) |
| BR (1) | BR112014029742A2 (zh) |
| CA (1) | CA2872181A1 (zh) |
| CL (1) | CL2014003325A1 (zh) |
| CO (1) | CO7151509A2 (zh) |
| CR (1) | CR20140528A (zh) |
| EA (1) | EA025273B1 (zh) |
| HK (1) | HK1206344A1 (zh) |
| IL (1) | IL236138A (zh) |
| MA (1) | MA37763B1 (zh) |
| MX (1) | MX2014014937A (zh) |
| NZ (1) | NZ702253A (zh) |
| PE (1) | PE20142450A1 (zh) |
| PH (1) | PH12014502623A1 (zh) |
| SG (1) | SG11201407576YA (zh) |
| UA (1) | UA113309C2 (zh) |
| WO (1) | WO2014001228A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0915500A2 (pt) | 2008-06-13 | 2019-08-27 | Shionogi & Co | derivado heterocíclico contendo enxofre tendo atividade inibitória de beta secretase |
| WO2011071135A1 (ja) | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | オキサジン誘導体 |
| WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
| TW201446758A (zh) | 2013-03-01 | 2014-12-16 | Amgen Inc | 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途 |
| WO2014138484A1 (en) | 2013-03-08 | 2014-09-12 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| JP6576433B2 (ja) | 2014-08-08 | 2019-09-18 | アムジエン・インコーポレーテツド | β−セクレターゼ阻害剤としてのシクロプロピル縮合チアジン−２−アミン化合物及び使用方法 |
| CN107406440B (zh) | 2015-03-20 | 2021-05-07 | 豪夫迈·罗氏有限公司 | Bace1抑制剂 |
| US11629154B2 (en) | 2018-04-27 | 2023-04-18 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| WO2011071135A1 (ja) * | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | オキサジン誘導体 |
-
2013
- 2013-06-24 UA UAA201500578A patent/UA113309C2/uk unknown
- 2013-06-24 EP EP13730887.0A patent/EP2864324B1/en not_active Not-in-force
- 2013-06-24 CA CA2872181A patent/CA2872181A1/en not_active Abandoned
- 2013-06-24 WO PCT/EP2013/063086 patent/WO2014001228A1/en active Application Filing
- 2013-06-24 KR KR20147036016A patent/KR20150023450A/ko not_active Withdrawn
- 2013-06-24 PE PE2014002406A patent/PE20142450A1/es not_active Application Discontinuation
- 2013-06-24 MA MA37763A patent/MA37763B1/fr unknown
- 2013-06-24 EA EA201590066A patent/EA025273B1/ru not_active IP Right Cessation
- 2013-06-24 NZ NZ702253A patent/NZ702253A/en not_active IP Right Cessation
- 2013-06-24 CN CN201380033783.7A patent/CN104470915B/zh not_active Expired - Fee Related
- 2013-06-24 MX MX2014014937A patent/MX2014014937A/es unknown
- 2013-06-24 SG SG11201407576YA patent/SG11201407576YA/en unknown
- 2013-06-24 AU AU2013283524A patent/AU2013283524B2/en not_active Expired - Fee Related
- 2013-06-24 JP JP2015519008A patent/JP6251257B2/ja not_active Expired - Fee Related
- 2013-06-24 US US14/406,289 patent/US9181232B2/en not_active Expired - Fee Related
- 2013-06-24 BR BR112014029742A patent/BR112014029742A2/pt not_active IP Right Cessation
-
2014
- 2014-11-18 CR CR20140528A patent/CR20140528A/es unknown
- 2014-11-24 PH PH12014502623A patent/PH12014502623A1/en unknown
- 2014-12-05 CL CL2014003325A patent/CL2014003325A1/es unknown
- 2014-12-08 IL IL236138A patent/IL236138A/en not_active IP Right Cessation
- 2014-12-10 CO CO14271199A patent/CO7151509A2/es unknown
-
2015
- 2015-07-21 HK HK15106931.2A patent/HK1206344A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| UA113309C2 (xx) | 2017-01-10 |
| CN104470915A (zh) | 2015-03-25 |
| IL236138A0 (en) | 2015-02-01 |
| WO2014001228A1 (en) | 2014-01-03 |
| MA37763B1 (fr) | 2017-05-31 |
| CO7151509A2 (es) | 2014-12-29 |
| SG11201407576YA (en) | 2015-03-30 |
| JP6251257B2 (ja) | 2017-12-20 |
| JP2015521640A (ja) | 2015-07-30 |
| EP2864324A1 (en) | 2015-04-29 |
| BR112014029742A2 (pt) | 2017-06-27 |
| US9181232B2 (en) | 2015-11-10 |
| CN104470915B (zh) | 2019-07-26 |
| AU2013283524B2 (en) | 2017-03-30 |
| MA37763A1 (fr) | 2016-08-31 |
| CA2872181A1 (en) | 2014-01-03 |
| MX2014014937A (es) | 2015-03-09 |
| EP2864324B1 (en) | 2018-03-28 |
| PH12014502623B1 (en) | 2015-01-21 |
| EA201590066A1 (ru) | 2015-04-30 |
| PH12014502623A1 (en) | 2015-01-21 |
| CL2014003325A1 (es) | 2015-04-24 |
| PE20142450A1 (es) | 2015-01-28 |
| NZ702253A (en) | 2016-06-24 |
| EA025273B1 (ru) | 2016-12-30 |
| KR20150023450A (ko) | 2015-03-05 |
| CR20140528A (es) | 2015-01-12 |
| US20150133440A1 (en) | 2015-05-14 |
| AU2013283524A1 (en) | 2014-11-13 |
| IL236138A (en) | 2016-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181595T1 (hr) | Bispecifična anti-vegf/anti-ang-2 protutijela i njihova upotreba u liječenju očnih krvožilnih bolesti | |
| HK1206344A1 (zh) | 作為 抑制劑的二氟-六氫-環戊二烯並噁嗪基類和二氟-六氫-苯並噁嗪基類 | |
| HK1213192A1 (zh) | 用於在人類受試者中治療眼部疾病的方法和裝置 | |
| EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
| HK1203478A1 (zh) | 用於治療糖尿病性視網膜病及其他眼科疾病的方法 | |
| IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
| HK1215868A1 (zh) | 雙特異性構建體及其用於治療多種疾病的用途 | |
| IL236920B (en) | Ophthalmic compositions and their use for treatment of eye diseases and disorders in animals | |
| IL274398A (en) | ANTI-IGF-1R antibodies that eliminate binding to FCRN and their use in the treatment of vascular diseases of the eye | |
| HK1211960A1 (zh) | 治療血管疾病及其併發症 | |
| ZA201401800B (en) | Novel plant defensins and use in the treatment of proliferative diseases | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230623 |